Royalty Pharma

30 results

Murray Kessler: When I leave a company that is stronger, that people have a good future in, then I’ll have done my job and I can go back to retirement.

Murray Kessler was retired when the call came from Perrigo. After a career in the tobacco and food sectors in the United States, he had turned his att(...)

Tysabri, the multiple sclerosis drug developed by Elan and subsequently acquired by Perrigo in 2013, has now been sold on to Royalty Pharma for up to €2.7 billion

Irish consumer healthcare and generic drug group Perrigo said has agreed to sell the royalty stream from its multiple sclerosis drug Tysabri to anothe(...)

Shareholders may have bloodied the nose of Elan management with their rejection of its investment plans at Monday’s extraordinary general meeting but, in its most recent update, Royalty had secured acceptances of less than 8 per cent of Elan’s stock.

Royalty Pharma has only itself to blame for the failed hostile bid to acquire Irish biotech group Elan for up to $8 billion. The Dublin-headquartered (...)

Royalty Pharma co-founder and chairman Rory Biggs. The US-based company has withdrawn its hostile bid for Irish drugmaker Elan.

MARY CAROLAN Royalty Pharma has withdrawn its court challenge to the Irish Takeover Panel’s decision requiring Royalty to lapse or withdraw its US$8 b(...)

Elan chairman Robert Ingram at the company’s EGM in Dublin today. Photograph: Aidan Crawley

Elan shareholders decisively rejected a major investment programme proposed by the company at a special meeting in Dublin today.However, investors nar(...)

Royalty Pharma’s $6.7 billion offer for Irish pharmacuetical firm Elan has now lapsed

Pharmaceutical firm Elan has initiated a formal sale process following the approval this morning of its share buyback programme. In accordance with(...)

Royalty Pharma’s hostile bid for Irish pharmaceutical firm Elan continues as its chairman asserts that “no other bona fide buyer” is interested in Elan. (Photo:John Cogill/Bloomberg News)

Ahead of Elan’s egm later today, at which shareholders will vote on a series of acquisitions undertaken by the Irish pharmaceutical firm, the chairman(...)

Independent News & Media shareholders will vote today on the proposed disposal of its South African assets as well as “a number of share capital a(...)

Elan chief executive Kelly Martin: the firm faces a critical moment in its volatile history with tomorrow’s EGM.

Irish biotech group Elan has been through many critical moments in its volatile history. Tomorrow, shareholders gather for an extraordinary general me(...)

One minute, Elan’s suitor, Royalty Pharma, was warning it might be forced to walk away as shareholders appeared certain to back a proposal by the Iris(...)

  • 1
  • 2
  • 3
  • Next
  • Last »